We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2022 to Apr 2024
Sanofi and Regeneron Pharmaceuticals Inc. said there are about 75,000 adults in the U.S. living with prurigo nodularis who are most in need of a new treatment option. "Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease," at 6:35 p.m. ET Sept. 28, incorrectly said the companies said there are about 75,000 adults in the U.S. living with prurigo nodularis.
(END) Dow Jones Newswires
September 30, 2022 14:56 ET (18:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
